FORT LAUDERDALE, FL--(Marketwired - Apr 22, 2015) - Golden Valley Development, Inc. (OTC PINK: GVDI) (the "Company"), a developer and marketer of patented and patentable technologies, is pleased to announce its latest product development in the healthcare sector: An advanced patentable chronic pain reduction formulation. The formula will be available for licensing following testing and release.

Pain is the leading cause of disability in the US, affecting more than cancer, diabetes and heart disease combined, according to the Life Science Industry Research Report. The global pain therapy and drug market size was over $50 billion in 2013, expected to grow at 10%. Worldwide, there are an estimated 1.5 billion people suffering from chronic pain and chronic pain related symptoms.

GVDI is in the final testing stages of a proprietary chronic pain reduction formulation. The formula will be available shortly after for licensing. The formula can treat a variety of chronic pain ailments such as Rheumatoid Arthritis. Key active ingredients include polysaccharides, triterpenoids and simple alkylphthalides, extracted and combined using a proprietary deep-heat and sequential isolation process from non-synthetic components. From a limited trial, the results also showed no side effects. More extensive studies and testing are being undertaken for its efficacy and side effects, however, it is believed that there will be no side effects compared to other existing formulas. More extensive studies are continuing, including targeted clinical trials. The formula will initially be for nutraceutical use and will be non-prescription, available over-the-counter, however, the application goes deeper. There will be two methods for application: direct skin application and oral consumption. The oral consumption will come in the form of a flattened square "gum stick" coated with thin rice paper, rendering it edible, as well as catalyzing and harmonizing the effect of usage. This is in contrast to the traditional pill/capsule design and method of delivery, which has both a slower activation time and less harmonizing effect. This innovative form is both environmentally friendly and revolutionary in medicinal application.

"We are very pleased to announce that we are now in the final testing stages of our new patentable chronic pain reduction formulation. The medical formula is to address chronic pain effectively without harmful side effects using medication containing steroids and cortisone, or products with major or harmful side effects," stated Kevin Sorrels, CEO of GVDI.

Non-steroidal anti-inflammatory drugs (NSAIDS) are the lead revenue generator of the global pain reduction market. NSAIDS encompass pain relief drugs, including ibuprofen and aspirin. The market for generic formulations, as compared to that of branded formulations, currently dominates the global pain management therapeutics market. The market of branded pain relieving drugs is highly fragmented with brands such as Pfizer, Inc., Eli Lilly & Co., and Purdue Pharma LP acquiring nearly 80% of total global revenues.

"Just like Percuguard™ and CutStop™, we have developed a unique product that represents a breakthrough in efficacy, packaging and method for delivery. We have created a top quality formula, which has multiple applications from prevention, supplementation and medicinal, which can be commercialized as nutraceuticals, supplement vitamins, and clinical applications. As soon as we have finalized the testing of our new formulation it would be made available for licensing and a multi-product roll out. We have already received serious inquires for clinical testing," added Kevin Sorrels, CEO of GVDI.

The company believes this formula will provide an effective and unique solution especially as it is proven to have no known side effects in the testing so far conducted. There is no guarantee that the product will have the same effect until proven in a wider commercial basis.

About Golden Valley Development, Inc.

Golden Valley Development, Inc. ("GVDI" or "Company") is a holding company, and developer and marketer of patented and patentable technologies. As a holding company, GVDI is focused in technology and financial services, engaging in several business activities, the most significant being as a technology provider to third party logistic providers and as a financial service company for small-to-medium sized businesses (SMEs) worldwide.

For additional information contact Investor Relations at:

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's OTC Markets disclosures and filings ( The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

Contact Information:

Golden Valley Development
Investor Relations